TITLE

NY leads search for AIDS vaccine

AUTHOR(S)
Scott, Gale
PUB. DATE
August 2006
SOURCE
Crain's New York Business;8/21/2006, Vol. 22 Issue 34, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports that clinical trials of several AIDS vaccines, including Merck & Co. Inc.'s AD-5 vaccine, are continuing at many major medical institutions in Manhattan, New York City. According to Beryl Koblin, head of the Laboratory of Infectious Disease Prevention for the New York Blood Center, the city has an important role to play in the search for a vaccine. Millions of dollars are spent annually on vaccine testing in the city.
ACCESSION #
22207084

 

Related Articles

  • New Orleans clinic begins human trials of HIV vaccine. Brannon, Keith // New Orleans CityBusiness (1994 to 2008);8/19/2002, Vol. 23 Issue 8, p8 

    Reports that physician Brobson Lutz's clinic in New Orleans, Louisiana will take part in phase one trials of a Merck and Co. HIV vaccine. Testing of whether a vaccine made from HIV-1 gag DNA is safe to use on people; Clinic's search for volunteers for the study; Design of the vaccine to cause...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Neurology Alert;Nov2007, Vol. 26 Issue 3, p2 

    The article reports on the announcement of Merck that their HIV vaccine is ineffective, after years of development and clinical trials. The company decided to halt further test vaccinations. The trials begun in 2004 wherein 3,000 uninfected volunteers in the U.S. and Latin were vaccinated....

  • Merck Sticks to Its Guns.  // Drug Discovery & Development;Apr2002, Vol. 5 Issue 4, p22 

    Reports the development of strong internal research program for creating breakthrough medications by Merck & Co. in the U.S. Increase of the expenditure Research & Development; Development of AIDS vaccine; Assistance of the company clinical trials.

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Clinical Cardiology Alert;Nov2007 Pharmacology Watch, p2 

    This article reports on the announcement by Merck that their HIV vaccine is ineffective after conducting a clinical trial. The company also announced that it stopped further test vaccinations. The vaccine developed by Merck works by stimulating T cells. There were a total of 3000 uninfected...

  • THE FIGHT AGAINST AIDS.  // Guide;Mar2005, Vol. 25 Issue 3, p120 

    Reports on developments concerning the fight against AIDS, as of March 2005. U.S. Food and Drug Administration's call on physicians to weigh the risks and benefits of nevirapine before prescribing it; Researchers' finding that taking AIDS drugs exactly as prescribed is the best way to prevent...

  • Merck HIV Vaccine Ineffective in Clinical Trial. Elliott, William T. // Clinical Oncology Alert;Nov2007 Pharmacology Watch, p2 

    The article reports on an announcement by Merck that their human immunodeficiency virus (HIV) vaccine is ineffective in a large clinical trial. After years of development and clinical trials, the company has stopped further test vaccinations. The Merck vaccine, which functioned by stimulating T...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Clinical Cardiology Alert;Nov2007, Vol. 26 Issue 11, p2 

    The article reports on the ineffectiveness of the HIV vaccine of Merck in a large clinical trial. It mentions that the vaccine worked by stimulating T cells. Its clinical trial involved 741 patients who received one dose of the vaccine and 762 patients who were given placebo. The failure of the...

  • Merck HIV Vaccine Ineffective in Clinical Trial. Elliott, William T. // Primary Care Reports;Nov2007, Vol. 13 Issue 11, p2 

    The article reports that Merck HIV vaccine was ineffective in a large clinical trial. Merck announced that it already halted further test vaccinations. Although work continues on other HIV vaccines, with 30 worldwide in clinical trials at present, the failure of the Merck vaccine is seen is a...

  • Fears over HIV vaccines laid to rest. Coghlan, Andy // New Scientist;7/25/2009, Vol. 203 Issue 2718, p14 

    The article reports that fears concerning HIV vaccines may encourage infection with the virus have been put aside, which could revive the search for a vaccine. It states that pharmaceutical company Merck stopped its STEP trial of an HIV vaccine in September 2007 because it does not appear to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics